• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Kyprolis Trumps Velcade in Multiple Myeloma Trial

Article

Results released by Amgen, who bought the molecule from Onyx, show that Kyprolis yielded better results when used as second-line in relapsed patients.

Patients with relapsed multiple myeloma benefited more from treatment with Amgen's Kyprolis than with Velcade, an older, rival drug marketed by Takeda, according to results from a study announced by Amgen on Sunday night.

Amgen believes proving Kyprolis' superiority over Velcade in the second-line multiple myeloma treatment setting further justifies the $10.4 billion paid for Onyx Pharmaceuticals, the developer of the drug. Another large study pitting the 2 drugs against each other in newly diagnosed multiple myeloma patients is ongoing with results expected next year.

Link to the Amgen press release:

http://bit.ly/17L8xyQ

Related Videos
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Emily Touloukian, DO, Coastal Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.